Bcl-2 immunostaining: A way to finding unresponsive postmenopausal N+*Breast cancer patients

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1213-1219

  Jalava, Paivi J ^a   Collan, Yrjö U I ^a   Kuopio, Teijo ^a   Juntti Patinen, Laura ^a   Kronqvist, Pauliina ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Bcl 2 immunostaining; Breast cancer; Estrogen receptor status; Lymph node status; Mammography; Menopause; Proliferative activity; Survival analysis

Indexed keywords

CELL DNA; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS INDEX; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; ODDS RATIO; POSTMENOPAUSE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0034053344     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Hurlimann J, Larrinaga B, Vala D: Bcl-2 protein in invasive ductal breast carcinomas. Virch Arch 426: 163-168, 1995.
2. Joensuu H, Pylkkanen L, Toikkanen S: Bcl-2 protein expression and long -term survival in breast cancer. Am J Pathol 145: 1191-1198, 1994.
3. Taylor C, Shi S, Chaiwun B, Young L, Imam S, Cote R: Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol 25: 263-270, 1994.
4. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957.
5. Baak JPA, van Dop H, Kurver PH, Hermans J: The value of morphometry to classic prognosticators in breast cancer. Cancer 56: 374-382, 1998.
6. Haapasalo H, Pesonen B, Collan Y: Volume corrected mitotic index (M/V index). The standard of mitotic activity in neoplasms. Path Res Pract 185: 551-554, 1989.
7. Collan YUI, Kuopio T, Baak JP, Becker R, Bogomoletz WV, Deverell M. et al: Standardized mitotic counts in breast cancer. Evaluation of the method. Path Res Pract 92: 931-941, 1996.
8. Baak JPA, Persijn JP: In search for the best qualitative microscopical or morphometrical predictor of oestrogen receptor in breast cancer. Path Res Pract 178: 307-314, 1984.
9. Collet D: Modelling survival data in medical research, London, Glasgow, New York, Tokyo, Melbourne, Madras: Chapman & Hall, 1994.
10. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354-360, 1995.
11. Kohayashi S, Iwase H, Ito Y, Yamashita H, Iwata H, Yamashita T, et al: Clinical significance of bcl-2 gene expression in human breast cancer tissues. Breast Cancer Res Treat 42: 173-181, 1997.
12. Binder C, Marx D, Overtoff R, Binder L, Schauer A, Hiddemann W: Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol 6: 1005-1010, 1995.
13. van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, et al: Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, hut docs not predict response to one course of perioperative chemotherapy. Br J Cancer 74: 78-85, 1996.
14. Silvestrini R, Benini E, Veneroni S, Daidone MG, Luisi A, Leutner M, et al: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604-1610, 1996.
15. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, et al: Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994.
16. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anhazhagar R, Jayatilake H. et al. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Study Group. Ann Oncol 5: 409-414, 1994.
17. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P. Mezzetti M. et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
18. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL: Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69: 135-139, 1994.
19. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K: Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 177: 49-55, 1995.
20. Sierra A, Lloverans B, Castellsague X, Moreno L, Garcia-Ramirez M, Fabni A: Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 60: 54-60, 1995.
21. Kronqvist P, Kuopio T, Collan Y: Morphometric grading of invasive ductal breast cancer. Thresholds for nuclear grading. Br J Cancer 78: 800-805, 1998.
22. Kuopio T, Kankaanranta A, Jalava P, Kronqvist P, Kotkansalo T, Weber E, et al: Cysteine proteinase inhibitor cystatin A in breast cancer. Cancer Res 58: 432-446, 1998.
23. Collan Y, Kuopio T, Auranen A, Linna M: Prognostication of breast cancer with multivariate methods. Adv Clin Pathol 1: 269-273, 1997.
24. Collan Y, Kumpusalo L, Pesonen E, Eskelinen M, Pajarinen P, Kettunen K: Prediction of survival in breast cancer: Evaluation of different multivariate models. Anticancer Res 18: 647-50, 1998.
25. Collan Y, Eskelinen MJ, Nordling SA, Lipponen P, Pesonen E, Kumpusalo LM et al: Prognostic studies in breast cancer. Multivariate combination of nodal status, proliferation index, tumor size, and DNA ploidy. Acta Oncol 33: 873-878, 1994.
26. Eskelinen MJ, Pajarinen P, Collan Y, Pesonen E, Alhava E, Kettunen K, et al: Relationship between ploidy and survival in patients with primary breast cancer. Br J Surg 76: 830-834, 1989.
27. Eskelinen M, Collan Y, Pajarinen P, Pesonen E, Kettunen K, Nordling S: An improved prognostic index of axillary node involvement in breast cancer incorporating DNA ploidy and tumor size. Acta Chir Scand 156: 521-527, 1990.